Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement.

Abstract

A 65-year-old man was hospitalized with IgG kappa-type multiple myeloma (MM) and enormous subcutaneous plasmacytomas. Two different combination chemotherapy regimens (MMCP and AVPP) and alpha-interferon therapy were ineffectual. Oral administration of etoposide at 50 mg/day was subsequently started, the tumors completely disappeared after 5 months. The… (More)

Topics

  • Presentations referencing similar topics